Skip to menu Skip to content Skip to footer
Professor Maher Gandhi
Professor

Maher Gandhi

Email: 

Overview

Background

Maher Gandhi received his medical degree in the UK in 1989, and then trained as a haematologist, including a Fellowship in malignant haematology at Princess Margaret Cancer Centre, Toronto. He was awarded a PhD in immunology at Cambridge University under Patrick Sissons. In 2003 he moved to Brisbane, and works as a Senior Staff Specialist (Pre-Eminent Status) in the Haematology / Oncology Department of the Princess Alexandra Hospital. He leads his own laboratory group and has established an international reputation studying immunity and identification of novel biomarkers in lymphoma, with continuous NHMRC funding since 2005. He was Chair of Laboratory Sciences for the Australasian Leukaemia and Lymphoma Group between 2010-2016, won the prestigious Australian Society of Medical Research Clinical Research Award in 2010 and in 2012 took up the inaugural John McCaffrey Cancer Council of Queensland / Office of Health and Medical Research Clinical Research Fellowship. Between 2011-2014 he was privileged to serve as Chair of the Metro South Human Research Ethics Committee. In 2013 he was appointed Professor of Experimental Haematology, University of Queensland, based at the Translational Research Institute, in 2014 became the inaugural Leukaemia Foundation Chair of Blood Cancer Research at the University of Queensland Diamantina Institute, and was appointed Diamantina Cancer Program Head in 2016. In 2018 to current, he moved to Mater Research, where he is Executive Director, as well Director of MRI-UQ.

Availability

Professor Maher Gandhi is:
Available for supervision
Media expert

Qualifications

  • Bachelor of Medicine Surgery, University of Aberdeen
  • Doctor of Philosophy, University of Cambridge

Research interests

  • Lymphoma

  • Immunotherapy

  • Biomarkers

Research impacts

The research of the Blood Cancer Research Laboratory aims to understand the basis of lymphoma; to devise new treatments which are less toxic and more effective; to establish new biomarkers which will help determine the most effective treatment strategies and to monitor response and relapse and understand the development of lymphomas. The group has a strong emphasis on patient material, which it obtains from international and national clinical collaborators. Lymphomas studied include Hodgkin Lymphoma, PTLD, Diffuse Large B-cell Lymphoma, Follicular Lymphoma and virus associated lymphomas. We utilise a broad range of approaches including genomics, molecular and cellular biology techniques and functional immunoassays. Several of our studies are linked with the Australasian Leukaemia and Lymphoma Group.

The Mater Foundation, the Leukaemia Foundation, and the Brisbane Girls Grammar School Kirsten Jack Memorial Fund are thanked for their kind support.

Works

Search Professor Maher Gandhi’s works on UQ eSpace

211 works between 1993 and 2024

161 - 180 of 211 works

2007

Conference Publication

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients

Mollee, P, Hourigan, M, Johnson, D, Jones, M, Isabel, N, Hawley, C, Marlton, P, Gandhi, M, Campbell, S and Gill, D (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. 49th Annual Meeting of the American-Society-of-Hematology, Atlanta Ga, Dec 08-11, 2007. WASHINGTON: BLACKWELL PUBLISHING.

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients

2007

Journal Article

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

Haque, T., Wilkie, G., Jones, M., Higgins, C., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M., Bellamy, C., Amlot, P., Kelly, D., MacGilchrist, A., Gandhi, M., Swerdlow A. and Crawford, D. (2007). Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood, 110 (4), 1123-1131. doi: 10.1182/blood-2006-12-063008

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

2007

Conference Publication

Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients

Hourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Ghandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients. American Transplant Congress 2007, USA, 5-9 May 2007. UK: Wiley-Blackwell Publising Ltd.. doi: 10.1111/j.1600-6143.2007.01811.x

Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients

2007

Journal Article

The use of T-cell directed cellular therapies in Australia

Moss, D.J., Khanna, R. and Gandhi, M. (2007). The use of T-cell directed cellular therapies in Australia. Cytotherapy, 9 (3), 222-224. doi: 10.1080/14653240701320288

The use of T-cell directed cellular therapies in Australia

2007

Conference Publication

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients

Hourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. American Transplant Congress, San Francisco, CA, USA, 5-9 May 2007. Oxford, England: Wiley-Blackwell. doi: 10.1111/j.1600-6143.2007.01811.x

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients

2007

Journal Article

The International Prognostic Index: the “gold-standard” in post-transplant lymphoproliferative disorders after renal transplantation

Hourigan, M. J., Mollee, P. N., Gill, D. S., Doecke, J., Norris, D., Johnson, D. W. and Gandhi, M. K.. (2007). The International Prognostic Index: the “gold-standard” in post-transplant lymphoproliferative disorders after renal transplantation. American Journal of Transplantation, 7, 399-399.

The International Prognostic Index: the “gold-standard” in post-transplant lymphoproliferative disorders after renal transplantation

2007

Journal Article

Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma

Gandhi, Maher K., Moll, Guido, Smith, Corey, Dua, Ujjwal, Lambley, Eleanore, Ramuz, Olivier, Gill, Devinder, Marlton, Paula, Seymour, John F. and Khanna, Rajiv (2007). Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma. Blood, 110 (4), 1326-1329. doi: 10.1182/blood-2007-01-066100

Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma

2006

Journal Article

Functional reversion of antigen-specific CD8(+) T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope

Smith, Corey, Cooper, Leanne, Burgess, Melinda, Rist, Michael, Webb, Natasha, Lambley, Eleanore, Tellam, Judy, Marlton, Paula, Seymour, John F., Gandhi, Maher and Khanna, Rajiv (2006). Functional reversion of antigen-specific CD8(+) T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. Journal of Immunology, 177 (7), 4897-4906. doi: 10.4049/jimmunol.177.7.4897

Functional reversion of antigen-specific CD8(+) T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope

2006

Journal Article

Epstein-Barr virus and advanced chronic lymphocytic leukemia: innocent until proven guilty? Commentary on: Tsimberidou et al. Epstein-Barr virus in patients with chronic lymphocytic leukemia: A pilot study. Leuk Lymphoma 2006; 47 : 827-836

Gandhi, M and Khanna, R (2006). Epstein-Barr virus and advanced chronic lymphocytic leukemia: innocent until proven guilty? Commentary on: Tsimberidou et al. Epstein-Barr virus in patients with chronic lymphocytic leukemia: A pilot study. Leuk Lymphoma 2006; 47 : 827-836. Leukemia & Lymphoma, 47 (5), 779-780. doi: 10.1080/10428190600580973

Epstein-Barr virus and advanced chronic lymphocytic leukemia: innocent until proven guilty? Commentary on: Tsimberidou et al. Epstein-Barr virus in patients with chronic lymphocytic leukemia: A pilot study. Leuk Lymphoma 2006; 47 : 827-836

2006

Journal Article

Epstein-Barr virus and advanced chronic lymphocytic leukemia: innocent until proven guilty?

Gandhi, Maher and Khanna, Rajiv (2006). Epstein-Barr virus and advanced chronic lymphocytic leukemia: innocent until proven guilty?. Leukemia and Lymphoma, 47 (5), 779-780. doi: 10.1080/10428190600580973

Epstein-Barr virus and advanced chronic lymphocytic leukemia: innocent until proven guilty?

2006

Journal Article

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8(+) T-cell function in Hodgkin lymphoma patients

Gandhi, M. K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J. and Khanna, R. (2006). Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8(+) T-cell function in Hodgkin lymphoma patients. Blood, 108 (7), 2280-2289. doi: 10.1182/blood-2006-04-015164

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8(+) T-cell function in Hodgkin lymphoma patients

2006

Journal Article

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma

Gandhi, M. K., Lambley, E., Burrows, J., Dua, U., Elliott, S., Shaw, P. J., Prince, H. M., Wolf, M., Clarke, K., Underhill, C., Mills, T., Mollee, P., Gill, D., Marlton, P., Seymour, J. F. and Khanna, R. (2006). Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clinical Cancer Research, 12 (2), 460-464. doi: 10.1158/1078-0432.CCR-05-2008

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma

2006

Journal Article

Correlation of T-cell immune response with spontaneous resolution and subsequent relapse of Hodgkin's lymphoma

Wilson, W. M., Dua, U., Grigg, A. P. and Gandhi, M. K. (2006). Correlation of T-cell immune response with spontaneous resolution and subsequent relapse of Hodgkin's lymphoma. Leukemia & Lymphoma, 47 (5), 871-876. doi: 10.1080/10428190600649562

Correlation of T-cell immune response with spontaneous resolution and subsequent relapse of Hodgkin's lymphoma

2006

Journal Article

Epstein-Barr virus-associated lymphomas

Gandhi, M. K. (2006). Epstein-Barr virus-associated lymphomas. Expert Review of Anti-Infective Therapy, 4 (1), 77-89. doi: 10.1586/14737140.4.1.77

Epstein-Barr virus-associated lymphomas

2005

Journal Article

Viruses and lymphoma

Gandhi, Maher K. and Khanna, Rajiv (2005). Viruses and lymphoma. Pathology, 37 (6), 420-433. doi: 10.1080/003130200500368303

Viruses and lymphoma

2005

Journal Article

Regulation of clinical research

Gandhi, Maher K. (2005). Regulation of clinical research. Clinical Medicine, 5 (3), 299-299. doi: 10.7861/clinmedicine.5-3-299

Regulation of clinical research

2005

Journal Article

Follicular lymphoma: Time for a re-think?

Gandhi, Maher K. and Marcus, Robert E. (2005). Follicular lymphoma: Time for a re-think?. Blood Reviews, 19 (3), 165-178. doi: 10.1016/j.blre.2004.09.001

Follicular lymphoma: Time for a re-think?

2005

Journal Article

Technology Insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies

Khanna, Rajiv, Moss, Denis and Gandhi, Maher (2005). Technology Insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nature Clinical Practice Oncology, 2 (3), 138-149. doi: 10.1038/ncponc0107

Technology Insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies

2005

Conference Publication

LAG-3 expressing lymphocytes suppress EBV latent membrane protein-specific T cell function in Hodgkins lymphoma patients

Gandhi, M, Lambley, E, Marlton, P, Gill, D, Seymour, J, Wolf, M, Prince, M, Elliott, S and Khanna, R (2005). LAG-3 expressing lymphocytes suppress EBV latent membrane protein-specific T cell function in Hodgkins lymphoma patients. 9th International Conference on Malignant Lymphoma, Lugano Switzerland, Jun 09-11, 2005. OXFORD: OXFORD UNIV PRESS.

LAG-3 expressing lymphocytes suppress EBV latent membrane protein-specific T cell function in Hodgkins lymphoma patients

2004

Journal Article

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments

Gandhi, Maher K. and Khanna, Rajiv (2004). Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infectious Diseases, 4 (12), 725-738. doi: 10.1016/S1473-3099(04)01202-2

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments

Funding

Past funding

  • 2019 - 2020
    Indolent Lymphoma: Establishing a prognostic score fit for the modern era
    The Leukaemia Foundation of Australia Limited
    Open grant
  • 2018 - 2019
    A novel immunotherapy strategy for lymphoma using artificial microRNA gene targeting
    Metro South Hospital and Health Service
    Open grant
  • 2017 - 2019
    Pre-clinical studies of anti-LAG3 in lymphoma
    Bristol-Myers Squibb Pharmaceuticals Pty Limited
    Open grant
  • 2017
    Improving the evidence base for resource allocation in indolent lymphoma
    Gilead Australia Fellowship
    Open grant
  • 2016 - 2018
    Prognosticator for Follicular lymphoma (FL) and Mantle celly lymphoma (MCL)
    Research Donation Generic
    Open grant
  • 2016 - 2017
    Blood biomarkers in Hodgkin Lymphoma
    PA Research Foundation NHMRC Infrastructure Support
    Open grant
  • 2016
    Marshaling NK-cells in the fight against blood cancers: a novel approach
    PA Research Foundation NHMRC Near Miss Grant
    Open grant
  • 2015 - 2016
    Funding Assistance for Gandhi laboratory
    Metro South Hospital and Health Service
    Open grant
  • 2015 - 2016
    Using single-cell transcriptomics to define T-cell tolerance in EBV+ lymphoma
    PA Research Foundation
    Open grant
  • 2014 - 2018
    Leukaemia Foundation Queensland Chair in Blood Cancer Research (2014-2019)
    Leukaemia Foundation
    Open grant
  • 2014 - 2017
    Circulating Biomarkers in advanced classical Hodgkin Lymphoma
    NHMRC Project Grant
    Open grant
  • 2013 - 2014
    Monocytic myeloid derived suppressor cells and antiCD20-antibody dependent cellular cytotoxicity in diffuse large B-cell lymphoma (Cancer Council Queensland grant administered by PAH)
    Metro South Hospital and Health Service
    Open grant

Supervision

Availability

Professor Maher Gandhi is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

Contact Professor Maher Gandhi directly for media enquiries about:

  • Biomarkers
  • Immunotherapy
  • Lymphoma

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au